Manufacturer of Controlled Substances; Notice of Registration, 17261-17262 [05-6698]
Download as PDF
<![CDATA[
17261
Federal Register / Vol. 70, No. 64 / Tuesday, April 5, 2005 / Notices
Drug
Schedule
Fentanyl (9801) ............................
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6701 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 391), EliElsohly Laboratories, Inc., Mahmoud A.
Elsohly PhD., 5 Industrial Park Drive,
Oxford, Mississippi 38655, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Thebaine (9333), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for use in analysis and drug test
standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of EliElsohly Laboratories, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
VerDate jul<14>2003
19:48 Apr 04, 2005
Jkt 205001
the public interest at this time. DEA has
investigated Eli-Elsohly Laboratories,
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6699 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importation of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(1)), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(b) authorizing the importation
of such substances, provide
manufacturers holding registrations for
the bulk manufacture of the substances
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 20,
1998, Ethical Nutritional, LLC, 176
University Parkway, Pomona, California
91768–4300, made application to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substances listed in Schedule
II.
The company plans to import small
quantities of the listed controlled
substance to manufacture homeopathic
medications for human consumption.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file written
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 5, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic classes
of controlled substances listed in
Schedules I or II are and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6700 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 391), Houba,
Inc., P.O. Box 190, 16235 State Road 17,
Culver, Indiana 46511, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedule II; and by
letter dated October 1, 2004, to modify
its name to Acura Pharmaceutical
Technologies, Inc., and change the
address by removing the P.O. Box 190.
Drug
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
E:\FR\FM\05APN1.SGM
05APN1
17262
Federal Register / Vol. 70, No. 64 / Tuesday, April 5, 2005 / Notices
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Houba, Inc., to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Houba,
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6698 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005 (70 FR 392–393),
Noramco Inc., Division of OrthoMcNeil, Inc., 500 Old Swedes Landing
Road, Wilmington, Delaware 19801,
made application by renewal and by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Dihydrocodeine
(9120), a basic class of controlled
substance listed in Schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Noramco Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
VerDate jul<14>2003
19:48 Apr 04, 2005
Jkt 205001
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6695 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 19, 2005,
Rhodes Technologies, 498 Washington
Street, Coventry, Rhode Island 02816,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
Schedules I and II:
Drug Enforcement Administration
Drug
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
Register on January 4, 2005, (70 FR 393),
Organichem Corporation, 33 Riverside
Avenue, Rensselaer, New York 12144,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Hydrocodone (9193) and Fentanyl
(9801), a basic class of controlled
substances listed in Schedule II.
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Organichem Corporation to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Organichem Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6702 Filed 4–4–05; 8:45 am]
Tetrahydrocannabinols (7370) .....
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Thebaine (9333) ...........................
Noroxymorphone (9668) ..............
Fentanyl (9801) ............................
Frm 00035
Fmt 4703
Sfmt 4703
I
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for conversion and distribution to its
customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than June 6, 2005.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6697 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
PO 00000
Schedule
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 70, Number 64 (Tuesday, April 5, 2005)]
[Notices]
[Pages 17261-17262]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6698]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated December 21, 2004, and published in the Federal
Register on January 4, 2005, (70 FR 391), Houba, Inc., P.O. Box 190,
16235 State Road 17, Culver, Indiana 46511, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
Schedule II; and by letter dated October 1, 2004, to modify its name to
Acura Pharmaceutical Technologies, Inc., and change the address by
removing the P.O. Box 190.
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
[[Page 17262]]
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Houba, Inc., to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Houba, Inc., to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with State and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-6698 Filed 4-4-05; 8:45 am]
BILLING CODE 4410-09-P
